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Introduction
Endogenously produced via γ -aminobutyric acid metabolism, γ -hydroxybutyrate (GHB) is a short-chain fatty acid naturally present in several mammalian tissues, including the brain (Maitre, 1997) . GHB is used therapeutically in the U.S. for the treatment of narcolepsy with cataplexy as sodium oxybate (Xyrem®) and for the treatment of alcohol withdrawal in Europe (Gallimberti et al., 2000) . GHB has also recently been recognized as a common drug of abuse. Overdose cases involving GHB and its precursors, 1,4-butanediol and γ -butyrolactone, have been reported in the U.S.
and other western countries resulting in GHB-induced coma, respiratory depression, and fatality (Caldicott et al., 2004; Zvosec et al., 2010 ).
Even at low, therapeutic doses GHB displays nonlinear pharmacokinetics in humans (Palatini et al., 1993) . In rats, this dose-dependence has been demonstrated to be due to saturable metabolism, saturable oral absorption, and saturable renal reabsorption (Lettieri and Fung, 1979; Arena and Fung, 1980; Morris et al., 2005) .
Saturable oral absorption and renal reabsorption have been explained by the concentration-dependent transport of GHB by monocarboxylate transporters (MCTs) (Morris et al., 2005; Wang et al., 2006; Lam et al., 2010) . MCTs are proton-coupled transporters with ubiquitous expression, including expression at the intestine, kidney, brain, and at the red blood cell (RBC) membrane. Human and rodent RBCs primarily express MCT1 and have been used extensively for the characterization of this transporter (Poole and Halestrap, 1993; Garcia et al., 1995; Merezhinskaya and Fishbein, 2009) . Although MCT-mediated transport has been demonstrated to govern several of the pharmacokinetic processes of GHB, the significance of transport by MCT1
at the RBC membrane is unknown. The blood/plasma partitioning of GHB, including the linearity of this partitioning over relevant therapeutic and overdose concentrations, has not been evaluated. 
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Transport of other monocarboxylates, most notably lactate, across the RBC membrane has been well-characterized. Lactate RBC transport has been demonstrated to be due to three distinct mechanisms: transport by MCT1, transport by the anion exchanger, AE1 or band 3, and passive diffusion, which is demonstrated to be minimal . At physiologic lactate concentrations, MCT-mediated transport has been identified as the primary mode of lactate transport across human and rat RBC membranes with band 3 transport being prominent at very high (>300 mM) lactate concentrations (Deuticke et al., 1978; Deuticke et al., 1982; Poole and Halestrap, 1993) .
GHB is a known MCT substrate; however, transport by band 3 has not been previously evaluated, and the relative contribution of these transporters to GHB transport across the RBC membrane is not known.
Increasing incidence of GHB abuse has been reported in the U.S. with no pharmacological treatment currently identified to treat GHB overdose. Due to MCTmediated renal reabsorption of GHB, increasing renal clearance via MCT inhibition represents a potential treatment strategy in GHB overdose cases. The co-administration of GHB with L-lactate and other MCT inhibitors has been demonstrated to be effective in our laboratory for increasing renal and total clearances of GHB in rats (Morris et al., 2005; Wang et al., 2008a; Wang et al., 2008b) . Due to ubiquitous MCT expression which governs GHB pharmacokinetics, in vivo administration of MCT inhibitors has the potential to affect other pharmacokinetic parameters of GHB along with that of renal clearance. There exists a lack of information regarding the in vivo blood/plasma partitioning of GHB, and as such the effect of MCT inhibitors on this partitioning is also unidentified. The purpose of this research was to characterize the transport of GHB at the RBC membrane and to determine GHB blood/plasma partitioning in vivo in the presence and absence of the competitive MCT inhibitor L-lactate.
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All surgery was performed under anesthesia with ketamine/xylazine. Animals administered GHB alone underwent implantation of a jugular vein cannula, and those administered GHB and L-lactate underwent implantation of jugular and femoral vein cannulae. Cannulae were flushed daily with 40 IU/mL heparinized saline to maintain patency. All animals were allowed a minimum of 72 hours for recovery from surgery before drug administration.
In vivo Experimental Protocol. To assess the in vivo blood/plasma (B/P) partitioning of GHB and the effect of L-lactate on the GHB B/P ratio, serial as well as sacrificial sampling studies were performed. In the first study, animals were sacrificed and blood and plasma collected at 10, 30, 60, 120, 150, 180, 210, 240 , and 300 minutes after intravenous GHB administration at doses of 400, 600, and 800 mg/kg (n=3 for each dose at each time point). Another set of animals was administered GHB 600 mg/kg 7 intravenously and L-lactate as a 330 mg/kg bolus followed by a 121 mg/kg/hr infusion and sacrificed at the same time points. In the second study, to assess individual blood/plasma ratios across a wide concentration range, along with individual GHB renal clearances, animals were administered GHB 1500 mg/kg intravenously and blood and plasma serially collected at 3, 10, 20, 30, 60, 120, 150, 180, 210, 240, 270, 300, 330, and 360 minutes. Urine samples were also collected at determined intervals up to 480 minutes. Another set of animals was administered GHB 1500 mg/kg intravenously and L-lactate as a 66 mg/kg bolus followed by a 302.5 mg/kg/hr infusion and samples were serially collected as for GHB alone. For serial sampling, n=4-5 animals per group. In each study, L-lactate was administered 5 minutes after GHB administration. GHB was administered via the jugular vein cannula as a 200 or 300 mg/ml solution in water. Llactate infusions were administered using a PicoPlus syringe pump (Harvard Appartus, Holliston, MA) as a 20 or 40 mg/mL solution in water via the femoral vein cannula.
Sample Analysis by LC/MS/MS. Sample Preparation. GHB blood, plasma, and urine concentrations were determined using a previously validated LC/MS/MS assay (Felmlee et al., 2010a; Felmlee et al., 2010b) with slight modification for blood sample analysis. was removed and diluted with 800 μ L double-distilled water, and the diluted samples extracted using an anion solid phase extraction procedure previously described (Raybon and Boje, 2007) using Bond Elut SAX cartridges (100 mg resin, 1 mL volume, Agilent
This article has not been copyedited and formatted. The final version may differ from this version. Alto, CA) which was connected to a PE Sciex API 3000 triple-quadrupole tandem mass spectrometer with a turbo ion spray (Applied Biosystems, Foster City, CA). Seven microliters of sample was injected onto an Xterra MS C18 column (250x2.1 mm id, 5 um particle size, Water Co., Milford, MA). GHB was eluted with a flow rate of 0.2 mL/min, 100 to 90% A over 5 min, 90 to 10% A from 5-7.5 min, and 10 to 100% A from 7.5-12 min. Mobile phase A was made up of 0.1% formic acid in 95/5 water/acetonitrile. Mobile phase B was made up of 0.1% formic acid in 5/95 water/acetonitrile. The limit of quantification for blood and plasma was 1 μ g/mL and 4 μ g/mL for urine. Mass spectrometer conditions and calibration ranges have been described previously (Felmlee et al., 2010a 
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MgCl 2 , and 10 mM HEPES at the specified pH values. Red blood cells were then made into a 40% suspension in uptake buffer. For uptake, an oil-stop technique was used similar to those previously described (Jarvis and Young, 1980; Endres et al., 2009 
Results
In vivo GHB blood/plasma partitioning. The in vivo blood/plasma partitioning is shown in Figure 1 and resulting B/P ratios in Table 1 . This partitioning appears linear over the entire in vivo range of concentrations. Concomitant L-lactate administration resulted in a similar B/P ratio as that for GHB alone. Comparing animals in which individual B/P ratios could be obtained due to serial sampling, the mean blood/plasma ratios were similar to that using pooled data from both sampling strategies, indicating that these ratios were representative of the entire dataset. From this set of experiments, the mean B/P ratio in animals administered GHB with L-lactate was not significantly different from that of animals administered GHB alone. However, in the same animals, this dose of L-lactate significantly increased renal and total clearances of GHB compared to that of GHB alone concentrations (<40 mM), the majority of GHB transport across the RBC membrane is MCT-mediated. These in vitro experiments also demonstrate a decrease in the affinity of GHB for MCT1 as pH increases, indicated by a much lower K m value at pH 6.5 compared to that at pH 7.4. A similar trend for L-lactate transport has been noted previously (Deuticke, 1982) , and our experiments confirm this effect of pH on MCTmediated transport of GHB. Likewise, although inhibition of GHB transport by 2 mM Llactate in rat kidney membrane vesicles expressing rMCT1 has been demonstrated at 14 vitro findings can explain our results observed in vivo. Considering a decrease in GHB and L-lactate affinity for MCT1 at physiologic blood pH compared to that of the lower pH in the renal tubule, nonlinearity and inhibition could be expected to occur in the kidney at doses in which these effects are not observed at the RBC membrane.
The resulting K m for GHB of 17.0 mM determined at pH 7.4 is considerably higher than that previously determined for rMCT1 in our laboratory of 4.6 mM (Wang et al., 2006) . This reported K m value of 4.6 mM was determined at pH 6.0 and, as the current study demonstrates, this value would be expected to be lower than that at pH 7.4. The reported value is similar to our currently reported value of 2.2 mM at pH 6.5 and is more relevant to MCT-mediated transport at the kidney rather than that in the blood. A K i value for L-lactate has also been previously determined, for inhibition of its own transport in rat RBCs at pH 7.4, to be 2.2 mM (Poole et al., 1990 ), a value much lower than our currently reported value of 19.1 mM. Although the reported K i value was assessed as physiologic blood pH, this value was determined at a very low temperature (6°C) due to rapid lactate transport kinetics. The values of K i and K m for MCT substrates have been observed to increase with temperature; several-fold differences have been reported as temperature is increased from 5 to 20°C (Deuticke, 1982; Poole and Halestrap, 1993) .
The IC 50 value determined at a higher temperature in our studies is expected to be much greater than the previously reported K i value. Our in vitro results, at a more relevant temperature, demonstrate no inhibition of GHB transport at the L-lactate concentrations reached in vivo, consistent with a lack of inhibition at the RBC in our in vivo studies.
Along with the effect of pH, other factors may contribute to the observed in vivo results, including the presence of sodium-coupled monocarboxylate transporters (SMCTs, SLC5A8 and SLC5A12) in the kidney, which transport both GHB and L-lactate (Ganapathy et al., 2008 (Halestrap, 1976) . Transstimulation may prevent saturation at steady-state in vivo, while this effect would not be observed in our unidirectional uptake experiments. Indeed, the K m and V max of L-lactate measured under equilibrium exchange have been shown to be much higher than that determined by unidirectional uptake or efflux (Deuticke, 1982) ; therefore this is likely also true for GHB. Additionally, due to rapid transport kinetics, in vitro experiments were performed at a temperature lower than the physiologic temperature of 37°C. Considering the discussed effects of temperature on MCT-mediated transport, the actual in vivo K m for GHB uptake may in fact be higher than our determined value at pH 7.4. Along with MCT-mediated transport, in vitro experiments also indicate that band 3 plays a role in GHB RBC transport. Although this transport contributes at high GHB concentrations, it is unlikely that this transport alone would explain the lack of saturation at the RBC membrane in vivo, as this effect would also be expected to occur in vitro, and was not observed in our studies.
In conclusion, the contribution of MCT-mediated transport of GHB at the red blood cell has been demonstrated to be significant at relevant in vivo concentrations, although this transport does not appear to be saturable with in vivo GHB administration.
This article has not been copyedited and formatted. The final version may differ from this version. 
